We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CAR-T therapy

News List

Juno ends development of CAR-T therapy JCAR015 following patient deaths firstwordpharma
March 03, 2017
Juno Therapeutics said that it will end development of the experimental CAR-T therapy JCAR015 in adults with relapsed or refractory acute lymphoblastic leukaemia (ALL) following safety issues observed in a mid-stage trial.
Kite Pharma reports positive six-month data for CAR-T therapy in non-Hodgkin lymphoma firstwordpharma
March 01, 2017
Kite Pharma on Tuesday reported positive six-month results from a mid-stage study investigating its experimental CAR-T therapy axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma.

Previous page 1 2 3 Next page